FDA review clears path for second coronavirus vaccine, this one developed by Moderna

SOURCE: Washington Post

By Carolyn Y. Johnson
Regulators, who confirmed the vaccine was 94 percent effective and raised no serious safety concerns, could authorize it as early as Friday.
By the end of the week, the United States could have two coronavirus vaccines.

A vaccine developed by biotechnology company Moderna appears poised for regulatory clearance after a detailed data review by Food and Drug Administration scientists confirmed the two-shot regimen was “highly effective” in a clinical trial and carried no serious safety concerns.

The FDA is likely to authorize the Moderna vaccine as soon as Friday, according to a person with knowledge of the situation who spoke on the condition of anonymity because they were not authorized to discuss the issue. Anticipating that decision shortly, Gen. Gustave Perna, who is overseeing the federal effort to distribute vaccines, said Monday that the United States was preparing to ship almost 6 million doses of the Moderna vaccines to 3,285 locations in the first week.

Click here to read the full story


Please enter your comment!
Please enter your name here